Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tietz

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Clinical Microbiology|June 16, 2005
Disseminated coinfection with Actinomyces graevenitzii and Mycobacterium tuberculosis: case report and review of the literatureAndreas Tietz, Kenneth E Aldridge, Julio E Figueroa
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 6, 2004
Guide to sexually transmitted disease resources on the InternetAndreas Tietz, Stephen C Davies, John S Moran
The Annals of Pharmacotherapy|December 31, 2002
Fulminant liver failure associated with clarithromycinAndreas Tietz, Markus H Heim, Urs Eriksson, et al.
European Journal of Gastroenterology & Hepatology|September 10, 2011
Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern EuropePetr Urbanek, Marian Oltman, Ljubomir Ivanovski, et al.
European Journal of Gastroenterology & Hepatology|April 20, 2011
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern EuropePetr Husa, Marian Oltman, Ljubomir Ivanovski, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2007
Throat swabs are necessary to reliably detect carriers of Staphylococcus aureusDominik Mertz, Reno Frei, Barbara Jaussi, et al.
Infection Control and Hospital Epidemiology|September 15, 2005
Octenidine hydrochloride for the care of central venous catheter insertion sites in severely immunocompromised patientsAndreas Tietz, Reno Frei, Marc Dangel, et al.
HIV Clinical Trials|February 7, 2012
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCVMilos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, et al.
Gastro Hep Advances|August 12, 2024
Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine LearningJörn M Schattenberg, Maria-Magdalena Balp, Brenda Reinhart, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 9, 2010
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal diseaseMarkus Peck-Radosavljevic, John Boletis, Fatih Besisik, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Clinical Microbiology|June 16, 2005
Disseminated coinfection with Actinomyces graevenitzii and Mycobacterium tuberculosis: case report and review of the literatureAndreas Tietz, Kenneth E Aldridge, Julio E Figueroa
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 6, 2004
Guide to sexually transmitted disease resources on the InternetAndreas Tietz, Stephen C Davies, John S Moran
The Annals of Pharmacotherapy|December 31, 2002
Fulminant liver failure associated with clarithromycinAndreas Tietz, Markus H Heim, Urs Eriksson, et al.
European Journal of Gastroenterology & Hepatology|September 10, 2011
Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern EuropePetr Urbanek, Marian Oltman, Ljubomir Ivanovski, et al.
European Journal of Gastroenterology & Hepatology|April 20, 2011
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern EuropePetr Husa, Marian Oltman, Ljubomir Ivanovski, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2007
Throat swabs are necessary to reliably detect carriers of Staphylococcus aureusDominik Mertz, Reno Frei, Barbara Jaussi, et al.
Infection Control and Hospital Epidemiology|September 15, 2005
Octenidine hydrochloride for the care of central venous catheter insertion sites in severely immunocompromised patientsAndreas Tietz, Reno Frei, Marc Dangel, et al.
HIV Clinical Trials|February 7, 2012
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCVMilos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, et al.
Gastro Hep Advances|August 12, 2024
Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine LearningJörn M Schattenberg, Maria-Magdalena Balp, Brenda Reinhart, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 9, 2010
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal diseaseMarkus Peck-Radosavljevic, John Boletis, Fatih Besisik, et al.
Pageof 2